MX2020002148A - Vectores adenoasociados recombinantes. - Google Patents
Vectores adenoasociados recombinantes.Info
- Publication number
- MX2020002148A MX2020002148A MX2020002148A MX2020002148A MX2020002148A MX 2020002148 A MX2020002148 A MX 2020002148A MX 2020002148 A MX2020002148 A MX 2020002148A MX 2020002148 A MX2020002148 A MX 2020002148A MX 2020002148 A MX2020002148 A MX 2020002148A
- Authority
- MX
- Mexico
- Prior art keywords
- vectors
- recombinant adeno
- aav
- associated vectors
- adeno
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 2
- 239000013607 AAV vector Substances 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550458P | 2017-08-25 | 2017-08-25 | |
| PCT/US2018/047466 WO2019040586A1 (en) | 2017-08-25 | 2018-08-22 | RECOMBINANT ADENO-ASSOCIATE VECTORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002148A true MX2020002148A (es) | 2020-07-20 |
Family
ID=65439655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002148A MX2020002148A (es) | 2017-08-25 | 2018-08-22 | Vectores adenoasociados recombinantes. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190085358A1 (enExample) |
| EP (1) | EP3655041A4 (enExample) |
| JP (1) | JP2020533968A (enExample) |
| KR (1) | KR20200042935A (enExample) |
| CN (1) | CN111163811A (enExample) |
| AU (1) | AU2018320849A1 (enExample) |
| CA (1) | CA3073937A1 (enExample) |
| IL (1) | IL272655A (enExample) |
| MX (1) | MX2020002148A (enExample) |
| WO (1) | WO2019040586A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005992A (es) | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. |
| JP2022546545A (ja) * | 2019-09-03 | 2022-11-04 | クリスタル バイオテック インコーポレイテッド | 先天性魚鱗癬の治療のための組成物及び方法 |
| IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| US20230330267A1 (en) * | 2020-09-04 | 2023-10-19 | Ohio State Innovation Foundation | Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain |
| WO2023044306A1 (en) * | 2021-09-14 | 2023-03-23 | California Institute Of Technology | Aav capsid variants |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2313784T3 (es) * | 1998-05-28 | 2009-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Vector aav5 y usos del mismo. |
| WO2000075365A2 (en) * | 1999-06-08 | 2000-12-14 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
| WO2004014222A2 (en) * | 2002-08-12 | 2004-02-19 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| US7427396B2 (en) * | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| US7838657B2 (en) * | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| EP2357010B1 (en) * | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| US9415121B2 (en) * | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
| EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| AU2013388083B2 (en) * | 2013-05-01 | 2019-08-22 | Genzyme Corporation | Compositions and methods for treating spinal muscular atrophy |
| HUE047996T2 (hu) * | 2013-07-22 | 2020-05-28 | Childrens Hospital Philadelphia | AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2015171547A1 (en) * | 2014-05-05 | 2015-11-12 | Ovid Therapeutics Inc. | Methods of treating cognitive impairment associated with neurodegenerative disorders |
| US20160060655A1 (en) * | 2014-05-30 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
| WO2015191508A1 (en) * | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10711270B2 (en) * | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
| AU2016366549B2 (en) * | 2015-12-11 | 2022-11-10 | California Institute Of Technology | Targeting peptides for directing adeno-associated viruses (AAVs) |
| JP7082050B2 (ja) * | 2015-12-14 | 2022-06-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脊髄性筋萎縮症の処置において有用なアデノ－関連ウイルスベクター |
| CN109476707B (zh) * | 2016-05-13 | 2022-12-02 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和其使用方法 |
| JP7291397B2 (ja) * | 2017-02-15 | 2023-06-15 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 血管系を通過する遺伝子移入の方法および組成物 |
| WO2018170223A1 (en) * | 2017-03-15 | 2018-09-20 | Ovid Therapeutics Inc. | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders |
| KR20200100735A (ko) * | 2017-12-20 | 2020-08-26 | 오비드 테라퓨틱스 인크. | 발작 장애 치료 시 hM4Di의 용도 |
| CN112739353A (zh) * | 2018-06-14 | 2021-04-30 | 奥维德医疗公司 | Mir-92a或mir-145在治疗安格曼综合征中的用途 |
| KR20210084459A (ko) * | 2018-09-26 | 2021-07-07 | 캘리포니아 인스티튜트 오브 테크놀로지 | 표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물 |
| US10557149B1 (en) * | 2019-07-15 | 2020-02-11 | Vigene Biosciences, Inc. | Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus |
| AU2020388634A1 (en) * | 2019-11-19 | 2022-06-23 | AskBio Inc. | Therapeutic adeno-associated virus comprising liver-specific promoters for treating Pompe disease and lysosomal disorders |
| WO2021113634A1 (en) * | 2019-12-05 | 2021-06-10 | The Board Of Regents Of The University Of Texas | Transgene cassettes designed to express a human mecp2 gene |
| CA3116391A1 (en) * | 2020-09-14 | 2022-03-14 | President And Fellows Of Harvard College | Recombinant adeno associated virus encoding clarin-1 and uses thereof |
| KR20230152008A (ko) * | 2021-02-03 | 2023-11-02 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 단백질 m 유사체 및 융합 단백질 및 이들의 항체 기능 억제 용도 |
| US20240197919A1 (en) * | 2021-05-04 | 2024-06-20 | California Institute Of Technology | Recombinant aavs for delivery to central nervous system and brain vasculature |
| CN114259502A (zh) * | 2021-12-24 | 2022-04-01 | 南京鼓楼医院 | 一种基于脂肪组织的中枢靶向递送siRNA的方法及应用 |
| CN115554418B (zh) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
-
2018
- 2018-08-22 AU AU2018320849A patent/AU2018320849A1/en not_active Abandoned
- 2018-08-22 JP JP2020511199A patent/JP2020533968A/ja active Pending
- 2018-08-22 EP EP18849356.3A patent/EP3655041A4/en not_active Withdrawn
- 2018-08-22 CN CN201880064381.6A patent/CN111163811A/zh active Pending
- 2018-08-22 CA CA3073937A patent/CA3073937A1/en active Pending
- 2018-08-22 KR KR1020207008689A patent/KR20200042935A/ko not_active Withdrawn
- 2018-08-22 US US16/108,393 patent/US20190085358A1/en not_active Abandoned
- 2018-08-22 MX MX2020002148A patent/MX2020002148A/es unknown
- 2018-08-22 WO PCT/US2018/047466 patent/WO2019040586A1/en not_active Ceased
-
2020
- 2020-02-13 IL IL272655A patent/IL272655A/en unknown
-
2021
- 2021-08-12 US US17/400,768 patent/US20210371880A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210371880A1 (en) | 2021-12-02 |
| WO2019040586A1 (en) | 2019-02-28 |
| US20190085358A1 (en) | 2019-03-21 |
| KR20200042935A (ko) | 2020-04-24 |
| CN111163811A (zh) | 2020-05-15 |
| EP3655041A1 (en) | 2020-05-27 |
| IL272655A (en) | 2020-03-31 |
| EP3655041A4 (en) | 2021-04-21 |
| JP2020533968A (ja) | 2020-11-26 |
| AU2018320849A1 (en) | 2020-03-05 |
| CA3073937A1 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002148A (es) | Vectores adenoasociados recombinantes. | |
| PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| WO2020028751A3 (en) | Aav variants with enhanced tropism | |
| PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| CA3087910C (en) | RAAV MODIFIED CAPSIDE PROTEIN FOR GENE THERAPY | |
| WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
| MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
| MX2022013963A (es) | Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas. | |
| MX2021004397A (es) | Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos. | |
| MX388331B (es) | Variantes de virus adenoasociado y métodos de uso de estas | |
| EA201792236A1 (ru) | Получение увеличенных в размере векторов на основе аденоассоциированного вируса | |
| MX367100B (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
| AU2017248121A1 (en) | T cell receptors | |
| AU2017248120A1 (en) | T cell receptors | |
| MY190926A (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| WO2012142434A3 (en) | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome | |
| MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
| CO2018003960A2 (es) | Virus adeno-asociado recombinante que comprende un ácido nucleico galgt2 | |
| MX2025008949A (es) | Arni variante | |
| MX2019008105A (es) | Virus. | |
| MX2021004688A (es) | Distrofinas miniaturizadas y usos de las mismas. | |
| EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
| WO2014036468A3 (en) | Aav mediated aquaporin gene transer to treat sjogren's syndrome |